RxDoctor Payments Data

Gilberto Rodriguez, MD

Infectious Disease · Miami, FLNPI 1205833597

Payments from drug & device makers

$5,073in general payments, 2019–2025

Across 256 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Viiv Healthcare Company$921
  • Johnson & Johnson$591
  • Insmed, Inc.$546
  • Gilead$440
  • Merck$416
  • plus $766 from 12 others

What the payments were for

  • Food & beverage$4,74894%
  • Education$3266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,073 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$145,749
Medicare patients
419
Services billed
2,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen91$369,912
BiktarvyBictegrav/Emtricit/Tenofov Ala83$356,174
JulucaDolutegravir/Rilpivirine98$353,558
TriumeqAbacavir/Dolutegravir/Lamivudi42$167,606
DovatoDolutegravir Sodium/Lamivudine48$145,633
OdefseyEmtricitab/Rilpiviri/Tenof Ala41$145,172
PrezcobixDarunavir/Cobicistat20$48,137
TivicayDolutegravir Sodium11$24,344
Darunavir12$18,088
Daptomycin26$9,630
Cefepime Hcl25$5,641
Vancomycin Hcl18$2,215
Cefadroxil45$1,817
Methenamine Hippurate48$1,548
Rifampin16$1,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$440$726,086174 claims
Viiv Healthcare CompanyJuluca, Triumeq, Dovato, Tivicay$921$691,141199 claims
Johnson & JohnsonPrezcobix$591$48,13720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →